S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.52 (-0.07%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   907.51 (+0.56%)
NIO   4.60 (-1.50%)
AMD   181.89 (+1.28%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.21 (+1.15%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.72 (-3.00%)
DIS   122.63 (+1.36%)
AMC   3.77 (-13.13%)
PFE   27.91 (+0.47%)
PYPL   66.85 (+0.42%)
XOM   115.41 (+0.38%)
S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.52 (-0.07%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   907.51 (+0.56%)
NIO   4.60 (-1.50%)
AMD   181.89 (+1.28%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.21 (+1.15%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.72 (-3.00%)
DIS   122.63 (+1.36%)
AMC   3.77 (-13.13%)
PFE   27.91 (+0.47%)
PYPL   66.85 (+0.42%)
XOM   115.41 (+0.38%)
S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.52 (-0.07%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   907.51 (+0.56%)
NIO   4.60 (-1.50%)
AMD   181.89 (+1.28%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.21 (+1.15%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.72 (-3.00%)
DIS   122.63 (+1.36%)
AMC   3.77 (-13.13%)
PFE   27.91 (+0.47%)
PYPL   66.85 (+0.42%)
XOM   115.41 (+0.38%)
S&P 500   5,254.28 (+0.11%)
DOW   39,750.83 (-0.02%)
QQQ   444.52 (-0.07%)
AAPL   170.86 (-1.41%)
MSFT   421.53 (+0.02%)
META   489.96 (-0.79%)
GOOGL   150.73 (-0.09%)
AMZN   181.07 (+0.69%)
TSLA   177.62 (-1.23%)
NVDA   907.51 (+0.56%)
NIO   4.60 (-1.50%)
AMD   181.89 (+1.28%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.21 (+1.15%)
MU   118.60 (-0.45%)
CGC   9.27 (-2.93%)
GE   174.72 (-3.00%)
DIS   122.63 (+1.36%)
AMC   3.77 (-13.13%)
PFE   27.91 (+0.47%)
PYPL   66.85 (+0.42%)
XOM   115.41 (+0.38%)
NASDAQ:NERV

Minerva Neurosciences (NERV) Stock Price, News & Analysis

$2.53
+0.03 (+1.20%)
(As of 11:08 AM ET)
Today's Range
$2.45
$2.59
50-Day Range
$2.52
$12.47
52-Week Range
$1.58
$13.49
Volume
11,047 shs
Average Volume
126,931 shs
Market Capitalization
$17.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Minerva Neurosciences MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
334.8% Upside
$11.00 Price Target
Short Interest
Healthy
0.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.89
Upright™ Environmental Score
News Sentiment
1.44mentions of Minerva Neurosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.57) to ($4.54) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.95 out of 5 stars

Medical Sector

196th out of 939 stocks

Pharmaceutical Preparations Industry

80th out of 433 stocks

NERV stock logo

About Minerva Neurosciences Stock (NASDAQ:NERV)

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

NERV Stock Price History

NERV Stock News Headlines

The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
Minerva schizophrenia drug rejected by FDA
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
2NERV : Minerva Neurosciences: Q4 Earnings Insights
Minerva Neurosciences: Q4 Earnings Snapshot
SUNW, NSTG and NERV among mid-day movers
Minerva Neurosciences Inc NERV
See More Headlines
Receive NERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/28/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NERV
Fax
N/A
Employees
9
Year Founded
2007

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$11.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+336.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-30,000,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($4.07) per share

Miscellaneous

Free Float
6,545,000
Market Cap
$17.61 million
Optionable
Not Optionable
Beta
0.22

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Remy Luthringer Ph.D. (Age 63)
    Executive Chairman & CEO
    Comp: $853.58k
  • Mr. Geoffrey Robin Race F.C.M.A. (Age 63)
    M.B.A., President
    Comp: $628.46k
  • Mr. Frederick W. Ahlholm CPA (Age 58)
    Senior VP, CFO & Secretary
    Comp: $567.49k
  • Mr. Joseph Reilly (Age 49)
    Senior VP & COO
    Comp: $461k
  • Mr. William B. Boni (Age 72)
    Vice President of Investor Relations & Corporate Communications
  • Prof. Michael Davidson M.D. (Age 74)
    Chief Medical Officer
    Comp: $657.47k
  • Dr. Ramana Kuchibhatla Ph.D.
    Senior VP and Head of Research & Development

NERV Stock Analysis - Frequently Asked Questions

Should I buy or sell Minerva Neurosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NERV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NERV, but not buy additional shares or sell existing shares.
View NERV analyst ratings
or view top-rated stocks.

What is Minerva Neurosciences' stock price target for 2024?

1 equities research analysts have issued 12 month price objectives for Minerva Neurosciences' shares. Their NERV share price targets range from $11.00 to $11.00. On average, they predict the company's share price to reach $11.00 in the next year. This suggests a possible upside of 334.8% from the stock's current price.
View analysts price targets for NERV
or view top-rated stocks among Wall Street analysts.

How have NERV shares performed in 2024?

Minerva Neurosciences' stock was trading at $6.15 on January 1st, 2024. Since then, NERV stock has decreased by 58.9% and is now trading at $2.53.
View the best growth stocks for 2024 here
.

Are investors shorting Minerva Neurosciences?

Minerva Neurosciences saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 38,300 shares, a drop of 68.7% from the February 29th total of 122,400 shares. Based on an average daily trading volume, of 120,200 shares, the short-interest ratio is presently 0.3 days. Currently, 0.7% of the company's stock are sold short.
View Minerva Neurosciences' Short Interest
.

When is Minerva Neurosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our NERV earnings forecast
.

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences, Inc. (NASDAQ:NERV) posted its quarterly earnings data on Thursday, February, 22nd. The biopharmaceutical company reported ($1.19) earnings per share for the quarter, missing the consensus estimate of ($0.88) by $0.31.

When did Minerva Neurosciences' stock split?

Shares of Minerva Neurosciences reverse split before market open on Tuesday, June 21st 2022. The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What other stocks do shareholders of Minerva Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD).

Who are Minerva Neurosciences' major shareholders?

Minerva Neurosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Northern Trust Corp (0.36%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Kupfer, Frederick W Ahlholm, Geoff Race and Remy Luthringer.
View institutional ownership trends
.

How do I buy shares of Minerva Neurosciences?

Shares of NERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NERV) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners